Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levocetirizine for exercise-induced airway obstruction in cold air
NL-OMON32040Phase 4Withdrawn
- Sponsor
- Medisch Spectrum Twente
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of levocetirizine in allergic rhinitis (AR) and asthma (2 arms), sponsored by Medisch Spectrum Twente. Primary endpoints: Reduction in exercise-induced fall of FEV1, Reduction in exercise-induced fall of MIF50 and 1 more. Planned start Jul 2008; status: withdrawn.
02
Drugs
levocetirizine
03
Conditions
allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on NL-OMON32040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32040.